'''Fractional dose vaccination'''<ref>{{Cite journal|date=2020-02-07|title=Modelling epidemics with fractional-dose vaccination in response to limited vaccine supply|url=https://www.sciencedirect.com/science/article/abs/pii/S0022519319304540|journal=Journal of Theoretical Biology|language=en|volume=486|pages=110085|doi=10.1016/j.jtbi.2019.110085|issn=0022-5193|last1=Chen |first1=Zhimin |last2=Liu |first2=Kaihui |last3=Liu |first3=Xiuxiang |last4=Lou |first4=Yijun |pmid=31758966 |hdl=10397/94076 |s2cid=208254350 |hdl-access=free }}</ref><ref name=":0">{{Cite journal|last1=Vannice|first1=Kirsten|last2=Wilder-Smith|first2=Annelies|last3=Hombach|first3=Joachim|date=2018-08-16|title=Fractional-Dose Yellow Fever Vaccination — Advancing the Evidence Base|url=https://doi.org/10.1056/NEJMp1803433|journal=New England Journal of Medicine|volume=379|issue=7|pages=603–605|doi=10.1056/NEJMp1803433|issn=0028-4793|pmid=29995585|s2cid=205114579 }}</ref> is a strategy to reduce the dose of a [[vaccine]] to achieve a [[vaccination policy]] goal that is more difficult to achieve with conventional vaccination approaches, including deploying a vaccine faster in a [[pandemic]],<ref name=":1">{{Cite journal|last=Hunziker|first=Patrick|date=2021-07-24|title=Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit|url=https://precisionnanomedicine.com/article/26101-personalized-dose-covid-19-vaccination-in-a-wave-of-virus-variants-of-concern-trading-individual-efficacy-for-societal-benefit|journal=Precision Nanomedicine|volume=4 |issue=3 |language=en|doi=10.33218/001c.26101|issn=2639-9431|doi-access=free}}</ref> reaching more individuals in the setting of limited healthcare budgets, or minimizing side effects due to the vaccine.

Fractional dose vaccination exploits the nonlinear [[Dose–response relationship|dose-response]] characteristics of a vaccine: If two persons can be vaccinated instead of one, but each one gets 2/3 of the protective efficacy, there is a net benefit at society scale for reducing the number of infections. If the healthcare budget is limited or only a limited amount of vaccine is available during the early phase of a pandemic, this can make a difference for the total number of infections.{{cn|date=March 2022}}

Fractional dose vaccination uses a fraction of the standard dose of a regular vaccine that is administered by the same, or an alternative route (often [[Subcutaneous injection|subcutaneously]] or [[Intradermal injection|intradermally]]).<ref>{{Cite journal|date=2020-09-01|title=Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis|journal=Travel Medicine and Infectious Disease|language=en|volume=37|pages=101868|doi=10.1016/j.tmaid.2020.101868|issn=1477-8939|pmc=7474844|last1=Schnyder |first1=Jenny L. |last2=De Pijper |first2=Cornelis A. |last3=Garcia Garrido |first3=Hannah M. |last4=Daams |first4=Joost G. |last5=Goorhuis |first5=Abraham |last6=Stijnis |first6=Cornelis |last7=Schaumburg |first7=Frieder |last8=Grobusch |first8=Martin P. |pmid=32898704 }}</ref>

Fractional dose vaccination has been used or proposed in a number of relevant infectious poverty diseases including [[yellow fever]],<ref name=":0" /> [[Polio|poliomyelitis]],<ref>{{Cite journal|last1=Resik|first1=Sonia|last2=Tejeda|first2=Alina|last3=Sutter|first3=Roland W.|last4=Diaz|first4=Manuel|last5=Sarmiento|first5=Luis|last6=Alemañi|first6=Nilda|last7=Garcia|first7=Gloria|last8=Fonseca|first8=Magilé|last9=Hung|first9=Lai Heng|last10=Kahn|first10=Anna-Lea|last11=Burton|first11=Anthony|date=2013-01-31|title=Priming after a Fractional Dose of Inactivated Poliovirus Vaccine|url=https://doi.org/10.1056/NEJMoa1202541|journal=New England Journal of Medicine|volume=368|issue=5|pages=416–424|doi=10.1056/NEJMoa1202541|issn=0028-4793|pmid=23363495}}</ref> [[COVID-19]].<ref>{{Cite medRxiv |last=Hunziker |first=Patrick |date=2021-03-07 |title=Vaccination strategies for minimizing loss of life in Covid-19 in a Europe lacking vaccines |language=en |medrxiv=10.1101/2021.01.29.21250747v6}}</ref>

==Use==
=== In the context of limited healthcare budgets ===
During the [[2016 Angola and DR Congo yellow fever outbreak|2016 yellow fever outbreak in Angola and the Democratic Republic of the Congo]], the WHO approved the use of fractional dose vaccination to deal with a potential shortage of vaccine.<ref>{{Cite journal |last=World Health Organization |date=2016-07-20 |title=Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response |url=https://apps.who.int/iris/handle/10665/246236 |journal=WHO Secretariat Information Paper |hdl=10665/246236 |language=en}}</ref> In August 2016, a large vaccination campaign in [[Kinshasa]] used 1/5 of the standard vaccine dose.<ref>{{Cite web |date=2 September 2016 |title=Millions protected in Africa's largest-ever emergency yellow fever vaccination campaign |url=https://www.who.int/news/item/02-09-2016-millions-protected-in-africa-s-largest-ever-emergency-yellow-fever-vaccination-campaign |access-date=2022-06-08 |website=WHO News Release |language=en}}</ref> In 2018 it was reported that fractional dose vaccination with 1/5 of the standard vaccine dose, administered intradermally, conferred protection for 10 years, as documented by a randomized clinical trial.<ref>{{Cite journal|last1=Roukens|first1=Anna H.E.|last2=van Halem|first2=Karlijn|last3=de Visser|first3=Adriëtte W.|last4=Visser|first4=Leo G.|date=2018-11-27|title=Long-Term Protection After Fractional-Dose Yellow Fever Vaccination|url=https://www.acpjournals.org/doi/full/10.7326/M18-1529|journal=Annals of Internal Medicine|volume=169|issue=11|pages=761–765|doi=10.7326/m18-1529|pmid=30476963 |s2cid=53737386 |issn=0003-4819}}</ref>

In [[Polio]]myelitis, fractional dose vaccination has been shown to be effective while reducing overall cost,<ref>{{Cite journal|date=2012-01-05|title=Intradermal fractional dose inactivated polio vaccine: A review of the literature|url=https://www.sciencedirect.com/science/article/pii/S0264410X11017853|journal=Vaccine|language=en|volume=30|issue=2|pages=121–125|doi=10.1016/j.vaccine.2011.11.018|issn=0264-410X|last1=Nelson |first1=Katherine S. |last2=Janssen |first2=Julia M. |last3=Troy |first3=Stephanie B. |last4=Maldonado |first4=Yvonne |pmid=22100886 }}</ref> rendering polio vaccination available to more individuals.

=== In the Covid-19 pandemic ===
In a pandemic wave, fractional dose vaccination is considered to accelerate widespread access to vaccination when vaccine supply is limited:

In the [[COVID-19 pandemic]], [[Epidemiological modelling|epidemiologic]] models predict a major benefit of personalized fractional dose vaccination strategies with certain vaccines in terms of case load, deaths, and shortening of the pandemic.<ref name=":1" /><ref>{{Cite journal|last=Hunziker|first=Patrick|date=2021-07-24|title=Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit|url=https://precisionnanomedicine.com/article/26101-personalized-dose-covid-19-vaccination-in-a-wave-of-virus-variants-of-concern-trading-individual-efficacy-for-societal-benefit|journal=Precision Nanomedicine|language=en|volume=4|issue=3|pages=805–820|doi=10.33218/001c.26101|doi-access=free}}</ref>

===To reduce side effects===
In some segments of the population, disease risk is lower but specific vaccine side effect risks may be increased.<ref>{{Cite web|last1=Wallace|first1=Megan|last2=Oliver|first2=Sara|date=2021-06-23|title=COVID-19 mRNA vaccines in adolescents and young adults: Benefit-risk discussion|url=https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/05-COVID-Wallace-508.pdf}}</ref> In such subpopulations, fractional dose vaccination might optimize the benefit-risk ratio of vaccination for an individuum and optimize the cost-benefit relation for society.{{cn|date=March 2022}}

== References ==
{{reflist}}

[[Category:Vaccination]]